

EBER CISH kit
For *In vitro* Diagnostic Use

1	AVAILABLE PRODUCT FORMATS	2
2	INTENDED PURPOSE OF THE PRODUCT	2
3	SUMMARY AND EXPLANATION	2
4	PRINCIPLE OF PROCEDURE	2
5	RECONSTITUTION, MIXING, DILUTION	3
6	ADDITIONAL REQUIRED MATERIAL NOT SUPPLIED	3
7	STORAGE AND STABILITY CONDITIONS	3
8	SPECIMEN PREPARATION	3
9	WARNINGS AND PRECAUTIONS	4
10	INSTRUCTIONS FOR USE	5
11	TROUBLESHOOTING	5
12	LIMITATIONS	5
13	PERFORMANCE CHARACTERISTICS	6
14	BIBLIOGRAPHY	6
15	LABEL AND BOX SYMBOLS	7
16	CHANGELOG	7



1 AVAILABLE PRODUCT FORMATS

Vitro Ref	Biocare Ref	Tests	Vitro Component Ref	Biocare Components Ref	Quantity x Volume
MAD-001893QHVSBC	EG021-VTR-CK-CE-NP	20	MAD-001893HSVS	EG021-VTR-CP-CE-NP	1 x 1.41mL
			MAD-001892QDVS	EG024-VTR-DIG-CE-NP	1 x 7mL
			MAD-011892QECVS	EG025-VTR-PK-CE-NP	1 x 14mL

Table 1. References and presentation

2 INTENDED PURPOSE OF THE PRODUCT

The EBER CISH kit is a qualitative automated test designed to detect Epstein-Barr Virus (EBV) in formalin-fixed paraffin-embedded (FFPE) tissue specimens through chromogenic *in situ* hybridization (CISH).

3 SUMMARY AND EXPLANATION

This EBER CISH test is an *in vitro* assay intended for the detection of EBV-infected cells in formalin-fixed, paraffin-embedded (FFPE) tissue samples. The assay employs chromogenic *in situ* hybridization (CISH) using a probe specific for EBER1 and EBER2 RNAs, which are abundantly expressed in latent EBV infections.

EBV (Human Herpesvirus 4) is a highly prevalent virus, infecting over 90% of adults worldwide. Following primary infection, EBV establishes lifelong latency, primarily in resting memory B lymphocytes, where it expresses a limited number of genes, including the EBER RNAs. EBER1 and EBER2 are non-coding RNAs that play critical roles in oncogenesis, immune evasion, and resistance to apoptosis. These RNAs are the most abundant EBV transcripts in latently infected cells and are highly conserved, making them ideal targets for *in situ* detection.

Latent EBV infection is associated with a spectrum of malignancies, including but not limited to classic type of Hodgkin's lymphoma, the endemic Burkitt lymphoma, plasmablastic lymphoma, certain NK/T cell lymphomas and T lymphoproliferative disorders that appear in transplanted and immunocompromised patients infected by the HIV virus.

4 PRINCIPLE OF PROCEDURE

Chromogenic *In Situ* Hybridization (CISH) is a molecular technique used to detect specific nucleic acid sequences in formalin-fixed, paraffin-embedded (FFPE) tissue sections. The EBER CISH kit is designed for the automatic qualitative detection of Epstein-Barr virus (EBV)-encoded RNA (EBER) in tissue specimens. The method is based on the hybridization of a labeled probe to complementary EBER sequences within infected cells. Following hybridization, the probe is visualized through an enzyme-conjugated detection system (peroxidase) and a chromogenic substrate (DAB). Enzymatic activation of the chromogen produces a visible reaction product at the hybridization site.

After chromogenic development, specimens may be counterstained and coverslipped. Results are interpreted using a standard light microscope.

5 RECONSTITUTION, MIXING, DILUTION

This product is provided in a ready-to-use format. It is not necessary to reconstitute, mix or dilute it.

6 ADDITIONAL REQUIRED MATERIAL NOT SUPPLIED

6.1 Reagents and materials

- Cover, Biocare Ref NPRI10002L2, Vitro Ref. MAD-003983VS
- Dewax Solution, Biocare Ref. NPRI10001T280, Vitro Ref. MAD-004080VS
- DAB Enhancer, Biocare Ref. NPRI10005L2, Vitro Ref. MAD-001560QV
- Contrast Hematoxylin HDH3, Biocare Ref. NPRI10006L2, Vitro Ref. MAD-HDH3-100VS
- TBS Tween 20 Buffer 10X, Biocare Ref. NPRI10007MM, Vitro Ref. MAD-004077R-10
- Cleaning Solution 10X, Biocare Ref. NPRI10008MM, Vitro Ref. MAD-003931CSVS
- Probe Cleaning Kit, Biocare Ref. NPRI10009KC10, Vitro Ref. MAD-PCLK
- Master Polymer Plus Detection System, Biocare Ref. NPRI10010T135, Vitro Ref. MAD-000237QKVSBC
- IHC Treated Slides, Biocare Ref. NPRI10011, Vitro Ref. MAD-15-188-55/100
- Mixing Tubes, Biocare Ref. NPP20001, Vitro Ref. MAD-60732-100

6.2 Equipment

- NeoPATH Pro
- Optical microscope and/or digital scanner of histological slides.

7 STORAGE AND STABILITY CONDITIONS

Component:	Use conditions
Storage conditions	Store at 2°-8°C and keep away from sources of intense heat/cold until the expiration date of the product.
In-use stability	Once open, keep at 2°-8°C until the expiration date of the product.
Shipping conditions	Shipment should be performed at 2-8°C.

Table 2. Storage and stability conditions.

The product is stable to the expiration date printed on the label when stored at 15°-25°C. Do not use after expiration date.

8 SPECIMEN PREPARATION

Paraffin Sections: Tissues fixed in *formalin* are suitable for use prior to paraffin embedding.



9 WARNINGS AND PRECAUTIONS

- **Read the instructions for use before using this product.** In case of atypical or unexpected results, please contact your Authorized Supplier/Distributor.
- **Professional Use.** This product is only intended for professional laboratory purposes, and it is not intended for pharmacological, domestic or any other type of use. When the product is used as an aid to diagnosis it should only be handled by trained users and in authorized laboratories.
- Do not use reagent after the expiration date printed on the label.
- **Rx Only Physician prescribed test.** This product is for professional use only on prescription by a physician or other healthcare professional.
- **Use:**
 - Specimens, before and after fixation, and all materials exposed to them, should be handled as if capable of transmitting infection and disposed of with proper precautions.
 - Microbial contamination of reagents may result in an increase in nonspecific staining or/and erroneous results.
 - Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
 - Do not use reagent after the expiration date printed on the label.
- **Serious incident.** Any serious incident related to the use of this product that involves or may involve a serious deterioration, temporary or permanent, of the state of health of a patient, user or other person, or even death, or a serious threat to public health, must be reported as soon as possible to the manufacturer by e-mail at regulatory@vitro.bio and to the competent Health Authority of the EU member state where the user or patient is established. If the user is located in USA, report any serious incidents related to this device by contacting the local distributor (information identified on the product labelling) and the applicable competent authority of the Member State. Incidents caused by misuse of the product or by the use of the product beyond the useful life established on its labeling will be the responsibility of the user.
- **The safety and disposal precautions are described in the Safety Data Sheet of this product.** The current version of the Safety Data Sheet (SDS) of this product can be downloaded in the web page www.vitro.bio or requested at regulatory@vitro.bio.
- **Waste disposal:** The handling of wastes generated by the use of the products commercialized by Vitro S.A. must be performed according to the applicable law in the country in which these products are being used. As reference, the following table indicates the classification of wastes generated by this kit according to the European Law, specifically according to the *European Commission Decision of December 18, 2014* amending decision 2000/532/CE on the list of waste pursuant to Directive 2008/98/EC of the European Parliament and of the Council:



POTENTIAL WASTE GENERATED AFTER USING THIS PRODUCT	ELW* CODE	TYPE OF WASTE ACCORDING TO ELW*
Container for reagents used classified as dangerous (according to the Safety Data Sheet).	150110	"Containers containing waste or contaminated by dangerous substances"
Aqueous liquid waste containing hazardous substances (not solvents).	161001	"Liquids generated from the use of automatic IHC/HIS instruments: - Waste deposit of immunostainers. - used PT-Module buffers"
Consumables (tubes, tips, etc.). Any element that has been in contact with tissue samples.	180103	"Waste whose collection and disposal is subject to special requirements in order to prevent infection"
Liquids containing solvents (xylol, haematoxylin, alcohol, eosin), generated from immunostaining techniques.	160506	"Laboratory chemicals consisting of or containing dangerous substances, including mixtures of laboratory chemicals".

Table 3. Classification of waste generated by the use of this kit according to the European Legislation. *ELW: *European Legislation of Waste*.

***Note: This classification is included as a general guideline of action, being under the final responsibility of the user the accomplishment of all the local, regional, and national regulations on the disposal of this type of materials.**

10 INSTRUCTIONS FOR USE

Place the reagent in the NeoPATH Pro before starting the CISH process in the instrument. Select the appropriate protocol from the instrument's menu and follow the on-screen instructions.

11 TROUBLESHOOTING

Follow the CISH recommendations according to NeoPATH Pro protocol. If atypical results occur, contact Vitro's Regulatory Department at regulatory@vitro.bio.

12 LIMITATIONS

- Results must be interpreted by qualified healthcare professional in the context of patient's clinical history, symptoms, and other diagnostic findings.
- The correct performance of the test depends on the quality of the sample.
- NeoPATH Pro and the ancillary reagents should be used with formalin-fixed paraffin-embedded tissue sections. The use of any other type of sample may generate erroneous results, and its performance must be verified beforehand.
- Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, freezing, thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids may produce artifacts, or false negative results. Inconsistent results may be due to variations in fixation and embedding methods, or to inherent irregularities within the tissue.
- Excessive or incomplete counterstaining may compromise proper interpretation of results.

- The manufacturer provides this reagent for use following the instructions for CISH on prepared tissue sections. Any deviation from recommended test procedures may invalidate declared expected results; appropriate controls must be employed and documented. Users who deviate from recommended test procedures must accept responsibility for interpretation of patient results under these circumstances.
- Tissues from individuals infected with hepatitis B virus and expressing hepatitis B surface antigen (HBsAg) may exhibit nonspecific staining with horseradish peroxidase.

13 PERFORMANCE CHARACTERISTICS

The intra-run and inter-run reproducibility of the Epstein Barr Virus (EBER) CISH Kit performance was evaluated by staining slides containing the same tissue on different instruments and operators. The staining results were consistent across all conditions, demonstrating 100% concordance in tissue samples and performing as expected.











14 BIBLIOGRAPHY

- Dunleavy K, Roschewski M, Wilson WH. Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes. *Curr Hematol Malig Rep.* 2012;7(3):208-215. doi:10.1007/s11899-012-0132-3.
- Maeda E, Akahane M, Kiryu S, et al. Spectrum of Epstein-Barr virus-related diseases: a pictorial review. *Jpn J Radiol.* 2009;27(1):4-19. doi:10.1007/s11604-008-0291-2.
- Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. *Hum Pathol.* 2007 Sep, 38 (9) :1293-304.
- Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. *Hum Pathol.* 2007;38(9):1293-1304. doi:10.1016/j.humpath.2007.05.020.
- Deyrup AT. Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. *Hum Pathol.* 2008;39(4):473-483. doi:10.1016/j.humpath.2007.10.030.
- Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. *Nat Rev Cancer.* 2004;4(10):757-768. doi:10.1038/nrc1452.
- Kekis PB, Murtin C, Künzli BM, et al. Epstein-Barr virus-associated lymphoepithelial carcinoma in the pancreas. *Pancreas.* 2004;28(1):98-102. doi:10.1097/00006676-200401000-00016.
- Jin L, Lloyd RV. In situ hybridization: methods and applications. *J Clin Lab Anal.* 1997;11(1):2-9. doi:10.1002/(SICI)1098-2825(1997)11:1<2::AID-JCLA2>3.0.CO;2-F.
- Qian X, Lloyd RV. Recent developments in signal amplification methods for in situ hybridization. *Diagn Mol Pathol.* 2003;12(1):1-13. doi:10.1097/00019606-200303000-00001.



15 LABEL AND BOX SYMBOLS

Explanation of the symbols of the product label and box:

	<i>In vitro</i> diagnostic medical device		Expiration date
	Catalog number		Temperature limit
	Lot code		Manufacturer
	Refer to the instructions for use		Safety data sheet
	Distributor		Importer

16 CHANGELOG

Date	Description
2025-08-20	Initial version.